ANTIHYPERTENSIVE EFFICACY OF CANDESARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION

dc.contributor.authorNorbo‘toyev Olimjon Mustafaqul o‘g‘li
dc.date.accessioned2025-12-31T15:38:05Z
dc.date.issued2023-11-20
dc.description.abstractThe benefits of lowering blood pressure (BP) to achieve and maintain target levels to reduce the risk of cardiovascular morbidity and mortality are well established. The renin-angiotensin system plays an important role in the regulation of blood pressure and is a target for some groups of antihypertensive drugs, including AT1 receptor blockers for angiotensin P., which include candesartan. Candesartan 8-32 mg 1 time / day is recommended for the treatment of adult patients with arterial hypertension (AH). Candesartan has been shown in many randomized clinical trials to be effective in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy and migraine in various adult patient populations, including patients with concomitant type 2 diabetes mellitus, metabolic syndrome or impaired renal function. Available data indicate that candesartan is a highly effective drug for the treatment of hypertension.
dc.formatapplication/pdf
dc.identifier.urihttps://scholarexpress.net/index.php/wbph/article/view/3397
dc.identifier.urihttps://asianeducationindex.com/handle/123456789/49516
dc.language.isoeng
dc.publisherScholar Express Journals
dc.relationhttps://scholarexpress.net/index.php/wbph/article/view/3397/2897
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceWorld Bulletin of Public Health; Vol. 28 (2023): WBPH; 54-61
dc.source2749-3644
dc.subjectangiotensin receptor blockers
dc.subjectcandesartan
dc.subjectarterial hypertension
dc.titleANTIHYPERTENSIVE EFFICACY OF CANDESARTAN IN PATIENTS WITH ARTERIAL HYPERTENSION
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Article

item.page.files

item.page.filesection.original.bundle

pagination.showing.labelpagination.showing.detail
loading.default
thumbnail.default.alt
item.page.filesection.name
ogli_2023_antihypertensive_efficacy_of_candesartan.pdf
item.page.filesection.size
213.06 KB
item.page.filesection.format
Adobe Portable Document Format

item.page.collections